滤泡性淋巴瘤 (FL) 是非霍奇金淋巴瘤 (NHL) 的惰性亚型，其特征是长期自然缓解/复发过程。我们的目的是按治疗方案 (LOT) 和不同国家评估 FL 患者的现实生活质量 (QoL)。数据来自 Adelphi FL 疾病特定计划™，这是一项针对医生和医生的横断面调查。 2021 年 6 月至 2022 年 1 月期间，他们在欧洲 [法国、德国、意大利、西班牙、英国 (UK)] 和美国 (美国) 的患者进行了调查。患者通过欧洲研究组织提供了人口统计数据和患者报告的结果癌症治疗生活质量问卷 (EORTC QLQ-C30)。双变量分析评估了 LOT [一线 (1L)、二线 (2L)、三线或更高线 (3L)] 和国家/地区的 QoL 与 NHL。患者 (n = 401) 的平均年龄 [标准差 (SD)] 66.0 (9.24) 岁，58.1% 为男性，41.9%/22.9% 为安娜堡 III/IV 期。与 NHL 参考值相比，FL 患者的平均 EORTC 全球健康状况 (GHS)/QoL、恶心/呕吐、疼痛、呼吸困难、食欲不振和腹泻评分在统计学上显着较差 (p < 0.05)。平均 (SD) GHS/QoL 从 1L [56.5 (22.21)] 恶化至 3L [50.4 (20.11)]。在后来的 LOT 中，身体和角色功能、疲劳、疼痛、呼吸困难和腹泻评分也显着恶化 (p < 0.05)。在所有功能领域，欧洲患者与美国患者的平均评分均显着较低 (p < 0.05)，几乎所有症状评分（不包括腹泻）均显着较高 (p < 0.05)。在后来的 LOT 中，患有 FL 的患者在大多数情况下的评分明显较差生活质量方面优于早期的 LOT。与美国患者相比，欧洲患者的功能明显较低，症状负担较高。这些现实世界的发现凸显了对新型 FL 疗法的需求，以减轻患者负担，对生活质量产生积极影响。© 2024。作者。

Follicular lymphoma (FL) is an indolent subtype of non-Hodgkin's lymphoma (NHL), characterized by a long natural course of remissions/relapses. We aimed to evaluate real-world quality of life (QoL) in patients with FL, by line of therapy (LOT), and across countries.Data were drawn from the Adelphi FL Disease Specific Programme™, a cross-sectional survey of physicians and their patients in Europe [France, Germany, Italy, Spain, the United Kingdom (UK)], and the United States (US) from June 2021 to January 2022. Patients provided demographics and patient-reported outcomes via the European Organisation for Research and Treatment of Cancer QoL questionnaire (EORTC QLQ-C30). Bivariate analysis assessed QoL versus NHL, across LOT [first line (1L), second line (2L), third line or later (3L+)] and country.Patients (n = 401) had a mean [standard deviation (SD)] age of 66.0 (9.24) years, 58.1% were male, and 41.9%/22.9% were Ann Arbor stage III/IV. Patients with FL mean EORTC global health status (GHS)/QoL, nausea/vomiting, pain, dyspnea, appetite loss, and diarrhea scores were statistically significantly worse (p < 0.05) versus the NHL reference values. Mean (SD) GHS/QoL worsened from 1L [56.5 (22.21)] to 3L+ [50.4 (20.11)]. Physical and role functioning, fatigue, pain, dyspnea, and diarrhea scores also significantly worsened across later LOTs (p < 0.05). Across all functional domains, mean scores were significantly lower (p < 0.05) and almost all symptom scores (excluding diarrhea) were significantly higher (p < 0.05) for European versus US patients.Patients with FL at later LOTs had significantly worse scores in most QoL aspects than earlier LOTs. European patients had significantly lower functioning and higher symptom burden than in the US. These real-world findings highlight the need for novel FL therapies that alleviate patient burden, positively impacting QoL.© 2024. The Author(s).